However, CEA appears to be an insufficiently sensitive tool for primary CRC screening, especially in the early stages of the disease (sensitivity and specificity for Dukes' A and B 36 and 87%, respectively) (94). This evidence concerns the gene CEACAM5 and colorectal carcinoma.